Johnson & Johnson (JNJ) Common Equity (2009 - 2026)

Johnson & Johnson has disclosed Common Equity across 18 years of filings, most recently posting $85.0 billion for Q2 2026.

• In Q2 2026, Common Equity rose 8.28% year-over-year to $85.0 billion; the TTM figure through Jun 2026 stood at $85.0 billion (up 8.28% YoY), while the FY2025 annual figure was $81.5 billion, up 14.06% from the prior year.
• Common Equity came in at $85.0 billion for Q2 2026 at Johnson & Johnson, up from $81.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $85.0 billion in Q2 2026 to a low of $68.8 billion in Q4 2023.
• Average Common Equity over 5 years is $75.3 billion, with a median of $74.7 billion recorded in 2022.
• Year-over-year, Common Equity grew 16.98% in 2022 and slipped 10.46% in 2023.
• Over 5 years, Common Equity stood at $74.6 billion in 2022, then fell by 7.81% to $68.8 billion in 2023, then advanced by 3.95% to $71.5 billion in 2024, then advanced by 14.06% to $81.5 billion in 2025, then grew by 4.2% to $85.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $85.0 billion in Q2 2026, $81.2 billion in Q1 2026, and $81.5 billion in Q4 2025.